CAMP4 Therapeutics Corporation (CAMP) AI Stock Analysis

• Market Cap: $76.01M
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.86
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 55
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 20,161,074
• 10 Day Avg. Volume: 141,089
• 30 Day Avg. Volume: 1,592,597
• PEG Ratio: -0.35
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 156.16
• P/FCF Ratio: -2.21
• Enterprise Value/Market Cap: -0.03
• Enterprise Value/Revenue: -0.68
• Enterprise Value/Gross Profit: -0.68
• Enterprise Value/Ebitda: 0.05
• 1Y Price Target: $8.50
• Price Target Upside: 107.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $4.50 ▲(9.76% Upside)

CAMP4 Therapeutics Corporation's overall stock score is primarily influenced by its challenging financial performance, which is a significant concern. However, positive technical indicators suggest potential short-term price appreciation. The valuation is weak due to negative earnings and lack of dividends, adding to the risk profile of the stock. Investors should be cautious and consider the high volatility and financial instability before making investment decisions.

Positive Factors

Innovative Business Model

The company's focus on RNA-targeted therapies positions it at the forefront of biotechnology, leveraging cutting-edge science to address genetic disorders, which could lead to significant breakthroughs and long-term growth.

Strategic Partnerships

Strategic partnerships with larger pharmaceutical companies provide financial support, enhance research capabilities, and expand market reach, contributing to sustainable revenue streams and potential growth opportunities.

High Gross Profit Margin

A high gross profit margin indicates efficient production and potential for profitability improvement, providing a buffer against operational inefficiencies and supporting future financial stability.

Negative Factors

High Leverage

High leverage poses financial risks, limiting flexibility and increasing vulnerability to economic downturns, which could impact the company's ability to invest in growth and innovation.

Negative Cash Flow

Negative cash flow reflects operational inefficiencies and liquidity challenges, potentially hindering the company's ability to fund research and development or capitalize on new opportunities.

Declining Revenue

The decline in revenue suggests instability in the company's core operations, which could undermine long-term growth prospects and investor confidence if not addressed through strategic improvements.

CAMP4 Therapeutics Corporation Business Overview & Revenue Model

Company Description

CAMP4 Therapeutics Corporation (CAMP) is a biotechnology company focused on harnessing the power of RNA biology to develop transformative therapies for patients with serious diseases. The company operates primarily in the biotechnology sector, with a strong emphasis on leveraging its proprietary CAMP4 platform, which utilizes advanced computational and experimental techniques to identify and develop novel therapeutic candidates. CAMP's core products and services include therapeutic programs targeting genetic disorders and other diseases, with a focus on RNA-targeted therapies that aim to modulate gene expression and restore normal cellular function.

How the Company Makes Money

CAMP4 Therapeutics primarily generates revenue through several key streams, including research collaborations, licensing agreements, and potential milestone payments from partnerships with larger pharmaceutical companies. The company often enters into strategic partnerships to co-develop its therapeutic candidates, which can provide upfront payments and ongoing funding for research and development. Additionally, CAMP may receive royalties on sales of products developed from its proprietary technologies. The success of its revenue model is significantly bolstered by the strong demand for innovative treatments in the biotechnology sector and the increasing interest from investors and partners in RNA-based therapies.

CAMP4 Therapeutics Corporation Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.80M	652.00K	350.00K	0.00	295.84M	308.59M
Gross Profit	3.80M	652.00K	350.00K	0.00	121.89M	122.41M
EBITDA	-53.58M	-51.39M	-50.20M	-44.12M	7.49M	18.13M
Net Income	-53.40M	-51.79M	-49.29M	-44.19M	-31.15M	-21.16M
Balance Sheet
Total Assets	51.27M	78.31M	54.95M	102.55M	402.29M	441.82M
Cash, Cash Equivalents and Short-Term Investments	39.05M	64.04M	38.38M	83.19M	91.11M	91.69M
Total Debt	7.22M	8.65M	11.69M	12.39M	209.17M	210.80M
Total Liabilities	11.29M	15.16M	178.68M	180.08M	322.11M	342.50M
Stockholders Equity	39.99M	63.14M	-123.73M	-77.53M	80.18M	99.32M
Cash Flow
Free Cash Flow	-47.68M	-46.00M	-44.83M	-42.57M	-17.52M	17.23M
Operating Cash Flow	-47.13M	-45.56M	-44.16M	-38.54M	-4.22M	28.59M
Investing Cash Flow	-506.00K	-441.00K	-678.00K	-4.03M	-7.58M	-13.69M
Financing Cash Flow	120.37M	71.66M	301.00K	100.16M	-2.64M	-27.32M

CAMP4 Therapeutics Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAMP, the sentiment is Positive. The current price of 4.1 is above the 20-day moving average (MA) of 3.93, above the 50-day MA of 3.34, and above the 200-day MA of 2.81, indicating a bullish trend. The MACD of 0.28 indicates Positive momentum. The RSI at 56.65 is Neutral, neither overbought nor oversold. The STOCH value of 68.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CAMP.

CAMP4 Therapeutics Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMP	55 Neutral	$76.01M	-1.47	-172.70%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARTV	45 Neutral	$87.69M	-1.16	-47.96%	―	―	―
BYSI	44 Neutral	$81.47M	-5.07	―	―	―	―
RLMD	41 Neutral	$289.67M	―	-196.79%	―	―	23.17%
INKT	38 Underperform	$57.94M	-4.51	―	―	―	41.90%
OSTX	27 Underperform	$64.38M	―	―	―	―	-137.19%

CAMP4 Therapeutics Corporation Corporate Events

CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01

On October 1, 2025, CAMP4 Therapeutics announced the initiation of GLP toxicology studies for its lead product candidate, CMP-SYNGAP-01, aimed at treating SYNGAP1-related disorders. The studies are a crucial step toward a clinical trial application, potentially leading to a Phase 1/2 clinical trial by the second half of 2026. SYNGAP1-related disorders, which significantly impact cognitive development, currently lack FDA-approved therapies, highlighting the potential impact of CAMP4’s innovative approach on the treatment landscape.

The most recent analyst rating on (CAMP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Therapeutics Secures $100M in Private Placement

On September 9, 2025, CAMP4 Therapeutics Corporation announced a Securities Purchase Agreement with accredited investors to raise up to $100 million through a private placement. The initial closing is expected on September 11, 2025, with $50 million in upfront proceeds to fund the development of its SYNGAP1 program and other corporate purposes. The second closing, contingent on regulatory milestones, could provide an additional $50 million. Concurrently, the company announced board and management changes, including the appointment of Doug Williams as Board Chair and the elevation of Daniel Tardiff to Chief Scientific Officer. This financing, led by Coastlands Capital, positions CAMP4 to advance its first-in-class treatment for SYNGAP1-related disorders into clinical trials by the second half of 2026.

The most recent analyst rating on (CAMP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Therapeutics Reports Q2 2025 Progress and Outlook

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing RNA-targeting therapeutics to treat genetic diseases by upregulating gene expression. In its second quarter 2025 earnings report, CAMP4 highlighted significant progress in its SYNGAP1 and CMP-CPS-001 programs, showcasing positive translational data and completing dosing in a key clinical trial cohort. The company reported cash reserves of $39.1 million as of June 30, 2025, with research and development expenses increasing to $10.3 million compared to the previous year. Despite a net loss of $12.6 million for the quarter, CAMP4 remains optimistic about its pipeline, with plans to initiate GLP toxicology studies for CMP-SYNGAP-01 and report further clinical trial data for CMP-CPS-001 in the coming months. Looking ahead, CAMP4 is poised to advance its clinical programs, potentially initiating a global Phase 1/2 trial for SYNGAP1-related disorders in the second half of 2026, while continuing to explore strategic opportunities for CMP-CPS-001.